Saltar al contenido
Merck

Documentos clave

Ver Toda la documentación

SML1581

Moxifloxacin hydrochloride

98.0 to 102.0% (HPLC)

Sinónimos:

12-8039, Avalox, BAY12-8039, 1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydropyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas

Acerca de este artículo

Fórmula empírica (notación de Hill):
C21H24FN3O4· HCl
Número CAS:
186826-86-8
Peso molecular:
437.89
NACRES:
NA.77
PubChem Substance ID:
329825971
UNSPSC Code:
12352200
MDL number:
MFCD00949117
Beilstein/REAXYS Number:
8377447
Assay:
98-102% (HPLC)
Form:
powder
Quality level:
100
Storage condition:
desiccated
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

Nombre del producto

Moxifloxacin hydrochloride, 98-102% (HPLC)

Quality Level

100

assay

98-102% (HPLC)

form

powder

storage condition

desiccated

color

light yellow to yellow

solubility

H2O: slightly soluble

storage temp.

−20°C

SMILES string

Cl.COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc4C(=O)C(=CN(C5CC5)c14)C(O)=O

InChI

1S/C21H24FN3O4.ClH/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24;/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28);1H/t11-,16+;/m0./s1

InChI key

IDIIJJHBXUESQI-DFIJPDEKSA-N

General description

Moxifloxacin is a fourth-generation synthetic fluoroquinolone antibacterial. Moxifloxacin is a 8-methoxy quinolone and differs from other quinolones.

Application

Moxifloxacin hydrochloride has been used to study its antibacterial action against bacteria that have grown to high density.

Biochem/physiol Actions

Moxifloxacin has proved to be effective in treating sinusitis, community-acquired respiratory tract infection, pneumonia and acute exacerbations of chronic bronchitis. It has improved anti-gram positive activity compared to other fluoroquinolone such as ciprofloxacin and ofloxacin. Moxifloxacin is useful in treating skin infections that is of bacterial origin. It is known to have proper penetration into peripheral tissues and inflammatory fluids. Fluoroquinolones stabilize DNA strand breaks created by DNA gyrase and topoisomerase IV by binding to the enzyme-DNA complex. Compared to mammalian DNA gyrase, moxifloxacin has 100 times higher affinity for bacterial DNA gyrase. Moxifloxacin is an antibiotic and works against both Gram-positive and Gram-negative bacteria. Moxifloxacin is being investigated for the treatment of multidrug-resistant tuberculosis.

Still not finding the right product?

Explore all of our products under

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 3 - Eye Irrit. 2

Clase de almacenamiento

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
0000515776
0000515776
0000148021
0000148021
0000452406

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

R C Walker et al.
Mayo Clinic proceedings, 66(12), 1249-1259 (1991-12-01)
The fluoroquinolone class of antibiotics promises to become as diverse and as important as beta-lactam agents. The fluoroquinolones inhibit bacterial DNA gyrase and are bactericidal. All fluoroquinolones have potent activity against most gram-negative bacteria; ciprofloxacin is the most active against
Structural identification and characterization of impurities in moxifloxacin.
Kumar Y R, et al.
Journal of Pharmaceutical and Biomedical Analysis, 34(5), 1125-1129 (2004)
Tomoko Hasunuma et al.
British journal of clinical pharmacology, 81(6), 1078-1090 (2016-01-17)
To examine whether strict control of clinical trial conditions could reduce apparent differences of pharmacokinetic (PK) parameters among ethnic groups. Open-label, single dose PK studies of moxifloxacin, simvastatin and meloxicam were conducted in healthy male subjects from three East Asian
Ver todos los artículos relacionados